Medicare & Medicaid
News articles in this section include actions by federal regulators like the CMS and HHS, as well as information on Medicare and state Medicaid coverage and benefits.
The White House is distancing itself from Speaker Nancy Pelosi's (D-Calif.) plan to lower drug prices, emphasizing support for a bipartisan plan in the Senate instead.
The average person with traditional Medicare coverage paid $5,460 out of their own pocket for health care in 2016...
The arrangement helps consumers who signed up for exchange plans rather than Medicare Part B coverage.
A family may pay more than $1,500 a month for ACA coverage
When Americans are asked whether they support a “Medicare for all” system that would replace all current insurance with a generous government program, a majority often say yes. But when they’re asked follow-up questions, they often reveal that they’re not familiar with the details of that plan — or that they would also be happy with other Democratic policy proposals.
Amid growing political discussion over growing the role of government in healthcare, Medicare chief Seema Verma is warning that the feds need to have “humility” in how they approach health reform.
The Committee for a Responsible Federal Budget (CRFB) on Monday released a paper providing its preliminary estimates for various ways to finance "Medicare for All," as the issue of how to pay for such a health plan has taken center stage in the Democratic presidential primary.
For Elizabeth Warren, it was supposed to be one more big idea in a campaign built around them: a promise that everyone could get government-funded health care, following the lead of her friend and fellow White House hopeful Bernie Sanders. Instead, "Medicare for All" is posing one of the biggest challenges to the Massachusetts senator's candidacy.
Prescription drug companies and trade groups shelled out millions of dollars to lobby Congress as it considered legislation aimed at reining in skyrocketing drug prices, according to new lobbying disclosure reports. The Pharmaceutical Research and Manufacturers of America (PhRMA) — the trade group representing branded drug companies — spent $6.2 million on lobbying in the third quarter of 2019, which ran from July through the end of September.
WASHINGTON — Democratic lawmakers in recent weeks have begun to advance an argument long seen as something of a third rail in U.S. politics: that slightly less biomedical innovation might be worth a dramatic reduction in drug prices. The surprising candor has come amid pushback to House Speaker Nancy Pelosi’s high-profile drug pricing bill, which the trade group PhRMA this month said represented “nuclear winter” for the development of new medicines.